welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
study id #: NCT03038399
condition: Duchenne Muscular Dystrophy
status: active, not recruiting
purpose:This long-term extension study is an open-label, multiple‑dose study to evaluate the long‑term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15‑002 Phase IIa and VBP15-003 Phase IIa extension core studies.
intervention:
Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
mechanism of action: Glucocorticoid to delay decline in muscle strength
results: https://clinicaltrials.gov/ct2/show/results/NCT03038399
last updated: October 05, 2019
rareRelated
-
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
-
A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givin...This is a 2-part, phase 2 study to asses...
-
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
-
Effect of Deflazacort and Prednisone Versus Placebo on Pulmonary Function in Boys with Duchenne Muscular Dystrophy W...Objective: To prospectively assess the ...
-
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
-
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
-
Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystro...Long-term glucocorticoid therapy has imp...
-
Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model ...The absence of functional dystrophin wit...
-
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophyObjective: To assess safety and efficac...